Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122

Journal of Viral Hepatitis

Volumn 20, Issue 3, 2013, Pages 158-166

  Van Der Meer, A J ^a   Farid, W R R ^a   Sonneveld, M J ^a   De Ruiter, P E ^a   Boonstra, A ^a   Van Vuuren, A J ^a   Verheij, J ^a   Hansen, B E ^a   De Knegt, R J ^a   Van Der Laan, L J W ^a   Janssen, H L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ALT; chronic hepatitis C; liver injury; microRNA; miRNA 122

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; MICRORNA 122; MICRORNA 192;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC PATIENT; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCREENING; VIRUS DETECTION; VIRUS LOAD;

ADULT; AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER; MALE; MICRORNAS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY;

EID: 84873459086     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12001     Document Type: Article

References (46)

1. Ambros V,. The functions of animal microRNAs. Nature 2004; 431 (7006): 350-355.
2. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116 (2): 281-297.
3. Chang J, Nicolas E, Marks D, et al,. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004; 1 (2): 106-113.
4. Chen L, Yan HX, Yang W, et al,. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009; 50 (2): 358-369.
5. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T,. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12 (9): 735-739.
6. Liang Y, Ridzon D, Wong L, Chen C,. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007; 8: 166.
7. Esau C, Davis S, Murray SF, et al,. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3 (2): 87-98.
8. Krutzfeldt J, Rajewsky N, Braich R, et al,. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438 (7068): 685-689.
9. Castoldi M, Vujic Spasic M, Altamura S, et al,. The liver-specific microRNA miR-122 controls systemic iron homeostasis in mice. J Clin Invest 2011; 121 (4): 1386-1396.
10. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P,. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309 (5740): 1577-1581.
11. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al,. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327 (5962): 198-201.
12. Marquez RT, Bandyopadhyay S, Wendlandt EB, et al,. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010; 90 (12): 1727-1736.
13. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS,. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009; 28 (40): 3526-3536.
14. Kutay H, Bai SM, Datta J, et al,. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99 (3): 671-678.
15. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W,. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15 (1): 31-33.
16. Gilad S, Meiri E, Yogev Y, et al,. Serum microRNAs are promising novel biomarkers. PLoS ONE 2008; 3 (9): e3148.
17. Mitchell PS, Parkin RK, Kroh EM, et al,. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Nat Acad Sci USA 2008; 105 (30): 10513-10518.
18. Reid G, Kirschner MB, Van Zandwijk N,. Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol Hematol 2010; 80 (2): 193-208.
19. Laterza OF, Lim L, Garrett-Engele PW, et al,. Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009; 55 (11): 1977-1983.
20. Wang K, Zhang S, Marzolf B, et al,. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Nat Acad Sci USA 2009; 106 (11): 4402-4407.
21. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N,. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005; 41 (2): 380-382.
22. Poynard T, Bedossa P, Opolon P,. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349 (9055): 825-832.
23. Ghany MG, Kleiner DE, Alter H, et al,. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124 (1): 97-104.
24. Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE,. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology 1999; 30 (5): 1307-1311.
25. Pradat P, Alberti A, Poynard T, et al,. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36 (4 Pt 1): 973-977.
26. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55 (2): 245-264.
27. Ishak K, Baptista A, Bianchi L, et al,. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22 (6): 696-699.
28. Volk ML, Tocco R, Saini S, Lok AS,. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009; 50 (6): 1750-1755.
29. Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L,. Circulating MicroRNAs in patients with chronic hepatitis C and Non-alcoholic fatty liver disease. PLoS ONE 2011; 6 (8): e23937.
30. Zhang Y, Jia Y, Zheng R, et al,. Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 2010; 56 (12): 1830-1838.
31. Farid WR, Pan Q, Van der Meer AJ, et al,. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 2012; 18 (3): 290-297.
32. Poynard T, McHutchison J, Manns M, et al,. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122 (5): 1303-1313.
33. Bihrer V, Friedrich-Rust M, Kronenberger B, et al,. Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2011; 106 (9): 1663-1669.
34. Waidmann O, Bihrer V, Pleli T, et al,. Serum microRNA-122 levels in different groups of patients with chronic hepatitis B virus infection. J Viral Hepat 2012; 19 (2): e58-e65.
35. Prati D, Taioli E, Zanella A, et al,. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002; 137 (1): 1-10.
36. Kaplan MM,. Alanine aminotransferase levels: what's normal? Ann Intern Med 2002; 137 (1): 49-51.
37. Bantel H, Lugering A, Poremba C, et al,. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001; 34 (4 Pt 1): 758-767.
38. Que FG, Gores GJ,. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology 1996; 110 (4): 1238-1243.
39. Bantel H, Lugering A, Heidemann J, et al,. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury. Hepatology 2004; 40 (5): 1078-1087.
40. Linder S, Havelka AM, Ueno T, Shoshan MC,. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett 2004; 214 (1): 1-9.
41. Ueno T, Toi M, Biven K, Bando H, Ogawa T, Linder S,. Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 2003; 39 (6): 769-774.
42. Starkey Lewis PJ, Dear J, Platt V, et al,. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011; 54 (5): 1767-1776.
43. Elyakim E, Sitbon E, Faerman A, et al,. hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy. Cancer Res 2010; 70 (20): 8077-8087.
44. Hezova R, Slaby O, Faltejskova P, et al,. microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell Immunol 2010; 260 (2): 70-74.
45. Jopling CL,. Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 2008; 36 (Pt 6): 1220-1223.
46. Janssen HL, Reesink HW, Zeuzem S, et al,. A randomized, double-blind, placebo (PLB) controlled safety and anti-viral proof of concept study of miravirsen (MIR), an oligonucleotide targeting mir-122, in treatment naïve patients with genotype 1 (GT1) chronic hcv infection. Hepatology 2011; 54 (Suppl. 1): 1430A.